Nello Mainolfi - Oct 17, 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce N. Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Oct 17, 2022
Transactions value $
$124,243
Form type
4
Date filed
10/17/2022, 08:09 PM
Previous filing
May 3, 2022
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $66.7K +32.1K +6.38% $2.08* 534K Oct 17, 2022 Direct
transaction KYMR Common Stock Options Exercise $57.6K +27.7K +5.18% $2.08* 562K Oct 17, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -32.1K -69.05% $0.00 14.4K Oct 17, 2022 Common Stock 32.1K $2.08 Direct F1
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -27.7K -4.82% $0.00 547K Oct 17, 2022 Common Stock 27.7K $2.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
F2 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.